Risk of severe allergic reactions to COVID‐19 vaccines among patients with allergic skin diseases – practical recommendations. A position statement of ETFAD with external experts.

Authors :: Ring, J.
Worm, M.
Wollenberg, A.
Thyssen, J.P.
Jakob, T.
Klimek, L.
Bangert, C.
Barbarot, S.
Bieber, T.
Bruin‐Weller, M.S.
Chernyshov, P.V.
Christen‐Zaech, S.
Cork, M.
Darsow, U.
Flohr, C.
Fölster‐Holst, R.
Gelmetti, C.
Gieler, U.
Gutermuth, J.
Heratizadeh, A.
Source :: Journal of the European Academy of Dermatology & Venereology. Jun2021, Vol. 35 Issue 6, pe362-e365. 4p.
Publication Year :: 2021
Abstract: Dr. Seneschal has been an investigator, speaker, or consultant for Novartis, Abbvie, Sanofi, LeoPharma and Eli Lilly. Dr. De Raeve is a consultant, member of scientific advisory boards and/ or received personal fees and non-financial support from LEO Pharma, Pierre Fabre, Sanofi-Genzyme and Bioderma. Dr. Vestergaard has been investigator, speaker, or consultant for Novartis, Abbvie, Sanofi, LeoPharma and Eli Lilly. [Extracted from the article]

Subjects :: *COVID-19 vaccines
*SKIN diseases
*ALLERGIES
*MEDICAL personnel
*ECZEMA
*PHYSICIANS

Full Text Access

Tools